Sarclisa Is Likely to Be Managed At Parity With Similar Drugs

On March 2, the FDA approved Sanofi’s Sarclisa (isatuximab-irfc) for the treatment of multiple myeloma, a hematologic malignancy. The move added another therapy to a class full of products, both indicated for the condition and used off label. Almost half of payers responding to a Zitter Insights survey said they anticipate their company will manage the new treatment on parity with other multiple myeloma drugs that have a similar indication.

The FDA approved Sarclisa, a CD39-directed cytolytic antibody, for use in combination with Pomalyst (pomalidomide) and dexamethasone (pom-dex or Pd) — the latter of which is available under multiple brand names — for the treatment of adults with relapsed refractory multiple myeloma who have received at least two therapies including Celgene Corp.’s Revlimid (lenalidomide) and a proteasome inhibitor (RSP 3/20, p. 8).

Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

businessman-holding-a-cellphone
January 12

More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends

READ MORE
fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
January 12

New FDA Approvals: FDA Gives Accelerated Approval to Mirati’s Krazati

READ MORE
tubes
January 12

FDA Approved Four New Gene Therapies, Other Novel Agents in 2022

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today